Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Catalent, Inc. Common Stock (NY:CTLT)

63.48 UNCHANGED
Last Price Updated: 7:00 PM EST, Dec 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Catalent, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
News headline image
Novo Nordisk's Dominance In Obesity & Diabetes Drug Market Backed by Strong Pipeline: Analyst Gives Outperform Rating ↗
BMO's coverage of Novo Nordisk, spotlighting its groundbreaking advancements in weight loss and diabetes drugs. Analysts foresee Novo and Eli Lilly maintaining dominance in the obesity market, fueled... 
Via Benzinga
News headline image
Robbins LLP is Investigating the Acquisition of Catalent, Inc. (CTLT) by Novo Holdings
From Robbins LLP
Via GlobeNewswire
News headline image
Beyond The Numbers: 6 Analysts Discuss Catalent Stock ↗
 
Via Benzinga
News headline image
Best Obesity Drug Stock: Eli Lilly, Novo Nordisk, or Viking Therapeutics? ↗
All three of these high-flying stocks could have more room to run. 
Via The Motley Fool
News headline image
(CTLT) - Analyzing Catalent's Short Interest ↗
 
Via Benzinga
News headline image
In-Depth Examination Of 5 Analyst Recommendations For Catalent ↗
 
Via Benzinga
News headline image
Earnings Outlook For Catalent ↗
 
Via Benzinga
News headline image
Week In Review: Three Multinationals Plan Investments In Southeast Asia Facilities ↗
Shanghai WuXi Biologics has broken ground on a $1.4 billion facility in Singapore. Meanwhile, Novo Nordisk announced plans to invest $556 million to expand its Tianjin city production facility. 
Via Talk Markets
News headline image
Did Novo Nordisk Just Get a Jump on Eli Lilly? ↗
A recent FDA announcement may have just put one company in the lead. 
Via The Motley Fool
News headline image
The Top 3 Pharma Stocks to Buy in March2024 ↗
Investors explore the top three biotechnology stocks to buy in 2024 which are leading the anti-obesity market surge. 
Via InvestorPlace
News headline image
Novo Nordisk Sets Timeframe For Its Next-Gen Experimental Obesity Drug ↗
"Novo Nordisk's optimism soars with promising early trial data for amycretin, an experimental weight loss pill. Expect significant weight loss and cardiovascular benefits. Phase 2 trial begins in late... 
Via Benzinga
News headline image
Catalent Publishes Fifth Annual Corporate Responsibility Report, Highlighting Progress and Reinforcing Long-Term Commitment
From Catalent, Inc.
Via Business Wire
News headline image
Escalating Demand for Obesity Drugs Creates Time-Sensitive Race for Eli Lilly, Novo Nordisk ↗
Eli Lilly's strategic collaborations with outsourcing partners for Zepbound (tirzepatide) production. Challenges persist as Eli Lilly and Novo Nordisk address production bottlenecks amid rising... 
Via Benzinga
News headline image
Prediction: Eli Lilly and Novo Nordisk Stock Could Just be Getting Started. Here's Why ↗
Eli Lilly and Novo Nordisk dominate the diabetes market thanks to blockbuster medications Mounjaro, Ozempic, and Rybelsus. 
Via The Motley Fool
News headline image
Record-High S&P 500 Propels SPY ETF To $500-Billion Milestone, Nvidia Tops $2 Trillion, Broadcom Surpasses Tesla ↗
U.S. stock market continues bull run, hitting record highs for S&P 500 and Nasdaq 100. SPY ETF surpasses $500 billion AUM, with other companies also reaching milestones. 
Via Benzinga
Topics ETFs Stocks
News headline image
Top Stocks Not Named Nvidia You Need To Know About In 2024: Here's What Investors Think About Them (Wall Street Vs. Reddit) ↗
Nvidia Corp. is one of the leading top stocks with 60% gain in 2024, but other lesser-known names have outperformed. 
Via Benzinga
News headline image
Eli Lilly, Novo Nordisk's Strategies Against New Weight-Loss Drug Competitors ↗
Zealand Pharma's drug showed positive results in 83% of patients in Phase 2 trials for MASH, heating up the race for new obesity drugs and pushing the company's shares 30% higher. 
Via Benzinga
News headline image
CATALENT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Catalent, Inc. - CTLT
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
S&P 500's surge to new highs: Bull trap hiding in plain sight?
Nvidia and Meta lead the S&P 500 rally, but there's cause for concern about a potential bull trap amid market volatility and a pivot to stable dividend payers. 
Via MarketBeat
Topics ETFs Economy Stocks
News headline image
Nearly Half Of S&P 500 Stocks Trade Below 50-Day Moving Average: Which One Is The Cheapest? ↗
Nearly half of S&P 500 stocks are below 50-day moving average, indicating poor market breadth. Only top 5 companies shielded from bearish pressures. 
Via Benzinga
Topics Stocks
News headline image
Novo Nordisk, Eli Lilly Stride To Boost Supply Shortage For Newly Found Holy Grail Of Miraculous Weight Loss Drugs ↗
Challenges and updates in the weight loss drug market, as Novo Nordisk and Eli Lilly address supply shortages for Wegovy and Mounjaro. Strategies to meet the increasing demand and potential market... 
Via Benzinga
News headline image
Novo Nordisk Is Scaling a Barrier to Growth. Should You Buy Its Stock Now? ↗
Even more revenue is on the way from additional sales of Wegovy. 
Via The Motley Fool
News headline image
Novo Nordisk Just Gave Investors $16.5 Billion More Reasons to Get Excited ↗
Novo Nordisk just made a unique acquisition to help bolster the supply of Wegovy and Ozempic. 
Via The Motley Fool
News headline image
Catalent, Inc. Reports Second Quarter Fiscal 2024 Results
From Catalent, Inc.
Via Business Wire
News headline image
US Stocks Set To Open Higher, Finish Week Stronger Amid Mixed Earnings: Analyst Sees Another Leg-Up Ahead Of Historically Weak March ↗
The upward momentum that has been in play in recent sessions could cushion the market, especially as most major indices are in uncharted territory. 
Via Benzinga
News headline image
Earnings Scheduled For February 9, 2024 ↗
Companies Reporting Before The Bell • TELUS (NYSE:TU) is expected to report quarterly earnings at $0.23 per share on revenue of $5.24 billion. 
Via Benzinga
News headline image
The Skinny On Novo Nordisk: Weight-Loss Meds Make Big Pharma A Big Foe For Food Industry ↗
Novo Nordisk's groundbreaking weight-loss treatments are causing concern in the food industry. CEOs are seeking advice from the company. 
Via Benzinga
News headline image
Can financial, healthcare, energy stocks rise as rates stay high?
Sectors including financials, healthcare, utilities and energy outperform as interest rates remain high, but some of those industries face challenges in 2024. 
Via MarketBeat
News headline image
Catalent's Bloomington Plant Making Novo Nordisk's Obesity Drug Faces FDA Scrutiny Regarding Drug Manufacturing Concerns ↗
Novo Nordisk faces manufacturing challenges and drug shortages for diabetes and weight loss drugs, impacting Wegovy and Ozempic. 
Via Benzinga
News headline image
Eli Lilly, Novo Nordisk Could Be First Trillion-Dollar Drug Stocks ↗
Thanks to weight loss and obesity drugs, Eli Lilly and Novo Nordisk could become the first trillion-dollar stocks in the pharma industry. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.